U.S. markets closed

KemPharm, Inc. (KMPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.09+0.02 (+0.14%)
At close: 4:00PM EDT
14.23 +0.14 (0.99%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close14.07
Open14.15
Bid13.85 x 1000
Ask14.13 x 1100
Day's Range13.86 - 14.22
52 Week Range3.84 - 22.08
Volume703,506
Avg. Volume1,015,853
Market Cap401.668M
Beta (5Y Monthly)3.36
PE Ratio (TTM)N/A
EPS (TTM)-6.83
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why KemPharm Stock Sank Today
    Motley Fool

    Why KemPharm Stock Sank Today

    Shares of KemPharm (NASDAQ: KMPH) were sinking 12.6% as of 3:33 p.m. EDT on Friday. The big drop came after the drugmaker announced the exercise of existing warrants and the issuance of new warrants. In KemPharm's latest transaction, holders with warrants that could have been exercised for nearly 6.2 million shares received a new deal.

  • KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
    GlobeNewswire

    KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

    CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash in exchange for the Company’s agreement to issue in a private placeme

  • KemPharm Issues Letter to Shareholders
    GlobeNewswire

    KemPharm Issues Letter to Shareholders

    CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2021 Annual Meeting of Stockholders to be held on June 17, 2021. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022. The